New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery
Our study was aimed at assessing the retinal binding of a new synthetic Brilliant Blue G (BBG) derivative (pure benzyl-Brilliant Blue G; PBB) ophthalmic formulation, to improve vitreoretinal surgery procedure. Protein affinity of the new molecule was evaluated in vitro (cell-free assay) and in silic...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00708/full |
id |
doaj-8ca85b8fae51463bb78464f6141ecb51 |
---|---|
record_format |
Article |
spelling |
doaj-8ca85b8fae51463bb78464f6141ecb512020-11-25T03:33:18ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-05-011110.3389/fphar.2020.00708545969New Brilliant Blue G Derivative as Pharmacological Tool in Retinal SurgeryAngelo Spadaro0Marco Rao1Miriam Lorenti2Mario Rosario Romano3Antonio Augello4Chiara Maria Eandi5Chiara Maria Eandi6Chiara Bianca Maria Platania7Filippo Drago8Filippo Drago9Claudio Bucolo10Claudio Bucolo11Department of Drug Sciences, University of Catania, Catania, ItalyDepartment of Drug Sciences, University of Catania, Catania, ItalyDepartment of Drug Sciences, University of Catania, Catania, ItalyBiomedical Sciences, Humanitas University, Milano, ItalySection of Hygiene and Food of Animal Origin (SIAOA - UFCM), Department of Veterinary Prevention, Azienda Sanitaria Provinciale (ASP - CT), Catania, ItalyDepartment of Ophthalmology, University of Lausanne, Hôpital Ophtalmique Jules-Gonin, Lausanne, SwitzerlandDepartment of Surgical Science, University of Torino, Torino, ItalyDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, ItalyDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, ItalyCenter for Research in Ocular Pharmacology-CERFO, University of Catania, Catania, ItalyDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, ItalyCenter for Research in Ocular Pharmacology-CERFO, University of Catania, Catania, ItalyOur study was aimed at assessing the retinal binding of a new synthetic Brilliant Blue G (BBG) derivative (pure benzyl-Brilliant Blue G; PBB) ophthalmic formulation, to improve vitreoretinal surgery procedure. Protein affinity of the new molecule was evaluated in vitro (cell-free assay) and in silico. Furthermore, an ex vivo model of vitreoretinal surgery was developed by using porcine eyes to assess the pharmacological profile of PBB, compared to commercial formulations based on BBG and methyl-BBG (Me-BBG). PBB showed a higher affinity for proteins (p < 0.05), compared to BBG and Me-BBG. In vitro and in silico studies demonstrated that the high selectivity of PBB could be related to high lipophilicity and binding affinity to fibronectin, the main component of the retinal internal limiting membrane (ILM). The PBB staining capabilities were evaluated in porcine eyes in comparison with BBG and Me-BBG. Forty microliters of each formulation were slowly placed over the retinal surface and removed after 30 s. After that, ILM peeling was carried out, and the retina collected. BBG, Me-BBG, and PBB quantification in ILM and retina tissues was carried out by HPLC analysis. PBB levels in the ILM were significantly (p < 0.05) higher compared to BBG and Me-BBG formulations. On the contrary, PBB showed a much lower (p < 0.05) distribution in retina (52 ng/mg tissue) compared to BBG and Me-BBG, in particular PBB levels were significantly (p < 0.05) lower. Therefore, the new synthetic Brilliant Blue derivative (PBB) showed a great ILM selectivity in comparison to underneath retinal layers. In conclusion, these findings had high translational impact with a tangible improving in ex vivo model of retinal surgery, suggesting a future use during surgical practice.https://www.frontiersin.org/article/10.3389/fphar.2020.00708/fullinner limiting membraneretinavitreoretinal surgeryBrilliant Blue Gpuckerdrug design |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Angelo Spadaro Marco Rao Miriam Lorenti Mario Rosario Romano Antonio Augello Chiara Maria Eandi Chiara Maria Eandi Chiara Bianca Maria Platania Filippo Drago Filippo Drago Claudio Bucolo Claudio Bucolo |
spellingShingle |
Angelo Spadaro Marco Rao Miriam Lorenti Mario Rosario Romano Antonio Augello Chiara Maria Eandi Chiara Maria Eandi Chiara Bianca Maria Platania Filippo Drago Filippo Drago Claudio Bucolo Claudio Bucolo New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery Frontiers in Pharmacology inner limiting membrane retina vitreoretinal surgery Brilliant Blue G pucker drug design |
author_facet |
Angelo Spadaro Marco Rao Miriam Lorenti Mario Rosario Romano Antonio Augello Chiara Maria Eandi Chiara Maria Eandi Chiara Bianca Maria Platania Filippo Drago Filippo Drago Claudio Bucolo Claudio Bucolo |
author_sort |
Angelo Spadaro |
title |
New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery |
title_short |
New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery |
title_full |
New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery |
title_fullStr |
New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery |
title_full_unstemmed |
New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery |
title_sort |
new brilliant blue g derivative as pharmacological tool in retinal surgery |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2020-05-01 |
description |
Our study was aimed at assessing the retinal binding of a new synthetic Brilliant Blue G (BBG) derivative (pure benzyl-Brilliant Blue G; PBB) ophthalmic formulation, to improve vitreoretinal surgery procedure. Protein affinity of the new molecule was evaluated in vitro (cell-free assay) and in silico. Furthermore, an ex vivo model of vitreoretinal surgery was developed by using porcine eyes to assess the pharmacological profile of PBB, compared to commercial formulations based on BBG and methyl-BBG (Me-BBG). PBB showed a higher affinity for proteins (p < 0.05), compared to BBG and Me-BBG. In vitro and in silico studies demonstrated that the high selectivity of PBB could be related to high lipophilicity and binding affinity to fibronectin, the main component of the retinal internal limiting membrane (ILM). The PBB staining capabilities were evaluated in porcine eyes in comparison with BBG and Me-BBG. Forty microliters of each formulation were slowly placed over the retinal surface and removed after 30 s. After that, ILM peeling was carried out, and the retina collected. BBG, Me-BBG, and PBB quantification in ILM and retina tissues was carried out by HPLC analysis. PBB levels in the ILM were significantly (p < 0.05) higher compared to BBG and Me-BBG formulations. On the contrary, PBB showed a much lower (p < 0.05) distribution in retina (52 ng/mg tissue) compared to BBG and Me-BBG, in particular PBB levels were significantly (p < 0.05) lower. Therefore, the new synthetic Brilliant Blue derivative (PBB) showed a great ILM selectivity in comparison to underneath retinal layers. In conclusion, these findings had high translational impact with a tangible improving in ex vivo model of retinal surgery, suggesting a future use during surgical practice. |
topic |
inner limiting membrane retina vitreoretinal surgery Brilliant Blue G pucker drug design |
url |
https://www.frontiersin.org/article/10.3389/fphar.2020.00708/full |
work_keys_str_mv |
AT angelospadaro newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT marcorao newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT miriamlorenti newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT mariorosarioromano newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT antonioaugello newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT chiaramariaeandi newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT chiaramariaeandi newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT chiarabiancamariaplatania newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT filippodrago newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT filippodrago newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT claudiobucolo newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery AT claudiobucolo newbrilliantbluegderivativeaspharmacologicaltoolinretinalsurgery |
_version_ |
1724563399414644736 |